Abstract:BackgroundYes-associated protein 1 (YAP1) is an effector of Hippo pathway, which is critical for regulating organ size, cell proliferation and tumor growth in mammals. Many previous studies have explored the relationship between YAP1 and various types of cancer. However, these studies were limited by the small samples size and the findings were inconsistent among them. Therefore, a meta-analysis was conducted to assess the association between YAP1 and malignancies.MethodsA systematic literature search was conducted for eligible studies in the PubMed, Corchane Library, Web of Knowledge, EMBASE and CBM disc databases from inception to August 1st 2014. After heterogeneity analysis, pooled harzad ratio (HR) with 95% confidence interval (95% CI) using both fixed and random effect models were estimated in STATA 10.0. Meta regression analysis, subgroup analysis and sensitivity analysis were performed to explore the potential sources of heterogeneity and to evaluate the robustness of the result. Publication bias was assessed by Egger's test and funnel plot.ResultsA total of 21 unique articles from 2009 to 2014, comprising 2983 patients, were analyzed in the meta-analysis. The association of YAP1 expression and overall survival time (OS) was evaluated in 20 studies including 2067 patients. Positive YAP1 showed poorer OS (HR = 1.826; 95% CI = 1.465-2.275; p < 0.002). For evaluating disease-free survival time (DFS), 10 studies with 1139 patients were analyzed. Positive YAP1 indicated worse DFS (HR = 2.114; 95% CI = 1.406-3.179; p < 0.001). Subgroup analysis showed that both positive nuclear YAP1 (HR = 1.390, 95% CI: 0.810-2.400, p = 0.729) and up-regulation overall YAP1 (HR = 2.237, 95% CI: 1.548-3.232, p < 0.001) had poorer OS for patients with malignancies. Similarly, both positive nuclear YAP1 (HR = 3.733, 95% CI: 1.469-9.483, p = 0.001) and up-regulation overall YAP1 (HR = 1.481, 95% CI: 1.163-1.886, p = 0.554) showed worse DFS. The patients with urogenital system cancer had the poorest OS (HR = 2.133, 95% CI: 1.549-2.937, p = 0.020). The patients with alimentary system cancer had the most significant impact on DFS (HR = 1.879, 95% CI: 1.537-2.297, p < 0.001).ConclusionBoth overall and nuclear YAP1 overexpression are intimately associated with adverse OS and DFS in numerous cancers, suggesting that YAP1 may act as a potential therapeutic targets of these malignancies in the future.

YAP is overexpressed in clear cell renal cell carcinoma and its knockdown reduces cell proliferation and induces cell cycle arrest and apoptosis.

Downregulation of YAP in Clear Cell Renal Cell Carcinoma Contributes to Poor Prognosis and Progressive Features.

YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells

YAP is a Critical Oncogene in Human Cholangiocarcinoma

Overexpression of Yes-Associated Protein Contributes to Progression and Poor Prognosis of Non-Small-cell Lung Cancer.

Yes-Associated Protein Contributes to the Development of Human Cutaneous Squamous Cell Carcinoma Via Activation of RAS.

Yes-associated Protein Expression is Associated with Poor Prognosis in Patients with Colorectal Cancer

Clinical and Prognostic Significance of Yes-associated Protein in Colorectal Cancer

Expression and clinical significance of YAP gene and protein in human renal carcinoma tissues

[Yes-associated protein (YAP) promotes invasion and migration of cutaneous squamous cell carcinoma cells by activating the PI3K/AKT pathway]

YAP1 expression in colorectal cancer confers the aggressive phenotypes via its target genes

Yes-associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis.

Yes-associated Protein (YAP) Predicts Poor Prognosis and Regulates Progression of Esophageal Squamous Cell Cancer Through Epithelial-Mesenchymal Transition.

Yes-associated protein overexpression in colon cancer and association with SW480 cells proliferation and invasion

YAP represses the TEAD-NF-κB complex and inhibits the growth of clear cell renal cell carcinoma

Expression and Significance of Yes-associated Protein and Large Tumor Suppressor Gene 1 in Renal Clear Cell Carcinoma

Loss of Yes-associated Protein Represents an Aggressive Subtype of Colorectal Cancer

Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues

Prognostic Value Of Yes-Associated Protein 1 (Yap1) In Various Cancers: A Meta-Analysis

Overexpression Of Yes-Associated Protein Contributes To Apoptosis Of Lung Cancer

YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients